Controlled degradation of extracellular matrix (ECM)1 is essential in physiological situations involving connective tissue remodeling, such as tissue morphogenesis, repair, and angiogenesis. On the other hand, excessive breakdown of connective tissue components plays an important role in destruction of functional tissue architecture, e.g. in rheumatoid arthritis, osteoarthritis, atherosclerosis, periodontitis, autoimmune blistering disorders of skin, and dermal photoaging as well as in invasion and metastasis of tumor cells (see Refs. 1-3). Matrix metalloproteinases (MMPs) are a family of structurally related zinc-dependent endopeptidases collectively capable of degrading essentially all ECM components, and they are implicated in ECM remodeling in the physiologic and pathologic situations mentioned above. At present, 18 human members of the MMP family have been characterized, and most of them can be divided into subgroups of collagenases, gelatinases, stromelysins, and membrane-type MMPs based on their substrate specificity and structure (1-3).Collagenase-1 (MMP-1), collagenase-2 (MMP-8), and collagenase-3 (MMP-13) are the principal neutral proteinases capable of degrading native fibrillar collagens in the extracellular space. They all cleave type I, II, and III collagens at a specific site, generating 3 ⁄4 N-terminal and 1 ⁄4 C-terminal fragments, which denature in physiological temperature and are further degraded by other MMPs, e.g. gelatinases (see Refs. 1-3). MMP-13 also cleaves type I collagen at N-terminal nonhelical telopeptide (4). MMP-1 cleaves type III collagen and MMP-8 type I collagen most effectively (1-3). MMP-13, in turn, cleaves fibrillar collagens with preference to type II collagen over type I and III collagens and displays 40-fold stronger gelatinase activity than MMP-1 and MMP-8 (5-7). In addition, MMP-13 degrades type IV, X, and XIV collagens, tenascin, fibronectin, and aggrecan core protein (8 -9). Apparently due to its exceptionally wide substrate specificity, the physiologic expression of MMP-13 is limited to situations in which rapid and effective remodeling of collagenous ECM takes place, i.e. fetal bone development and adult bone remodeling (10, 11). On the other hand, MMP-13 is expressed at sites of excessive degradation of